| Status: Superseded | |||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED OCTOBER 2017. Refer to TA481: Immunosuppressive therapy for kidney transplant in adults for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
|||
|
|||
Medicine details |
|||
| Medicine name | tacrolimus (Advagraf®) | ||
| Formulation | 0.5 mg, 1 mg, 3 mg, 5 mg prolonged-release capsule | ||
| Reference number | 820 | ||
| Indication | Prophylaxis of transplant rejection in adult kidney or liver allograft recipients and the treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients |
||
| Company | Astellas Pharma Ltd | ||
| BNF chapter | Malignant disease & immunosuppression | ||
| Assessment type | Resubmission | ||
| Status | Superseded | ||
| Advice number | 0811 | ||
| NMG meeting date | 11/05/2011 | ||
| AWMSG meeting date | 15/06/2011 | ||
| Ratification by Welsh Government | 01/09/2011 | ||
| Date of issue | 07/09/2011 | ||
| NICE guidance | TA481: Immunosuppressive therapy for kidney transplant in adults (external website - opens in new window) |
||